Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study  Kenji Kabashima, MD, PhD, Masutaka.

Published bySara Møller Modified over 5 years ago

Similar presentations

Presentation on theme: "Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study  Kenji Kabashima, MD, PhD, Masutaka."— Presentation transcript:

1 Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study  Kenji Kabashima, MD, PhD, Masutaka Furue, MD, PhD, Jon M. Hanifin, MD, Grazyna Pulka, MD, Andreas Wollenberg, MD, Ryszard Galus, MD, PhD, Takafumi Etoh, MD, Ryosuke Mihara, MS, Miwa Nakano, MS, Thomas Ruzicka, MD  Journal of Allergy and Clinical Immunology  Volume 142, Issue 4, Pages e7 (October 2018) DOI: /j.jaci Copyright © 2018 The Authors Terms and Conditions

2 Fig 1 Study design. *Patients in the nemolizumab 2.0 mg/kg Q8W group received placebo at week 4 during part A; during part B, patients received placebo at week 12, nemolizumab at week 16, and then alternating doses of placebo and nemolizumab. **Number of patients who randomized to part B. †Number of patients at week 64. ‡Safety follow-up was performed 12 weeks after the last dose of study drug. FU, Follow-up; TCI, topical calcineurin inhibitor; TCS, topical glucocorticosteroid; w, week. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

3 Fig 2 Pruritus VAS (ITT population who received nemolizumab in part A, including data after rescue therapy). A, Percentage change from baseline in pruritus VAS score. Data are presented as means (SEs). B, Proportion of patients with a pruritus VAS score of less than 30 mm (post hoc analysis). ITT, Intent-to-treat. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

4 Fig 3 Change from baseline in key secondary and exploratory end points (ITT population who received nemolizumab in part A, includes data after rescue therapy). A, Percentage change in EASI score (mean ± SE). B, Proportion of patients with an sIGA score of 0 or 1 (percentage). C, Percentage change from baseline in sleep disturbance VAS (mean ± SE). D, Proportion of patients with a 4-point or greater decrease in DLQI (percentage; post hoc analysis). ITT, Intent-to-treat. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

5 Fig E1 Patient disposition. Completion of safety follow-up for patients who received nemolizumab in part A is the sum of patients who completed part A and a safety follow-up visit but who did not transition to part B plus patients who completed part B and a safety follow-up visit. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

Download ppt "Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study  Kenji Kabashima, MD, PhD, Masutaka."

Similar presentations

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.
Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis  Kristian Reich, MD, PhD, Julia Deinzer,

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis  Kristian Reich, MD, PhD, Julia Deinzer,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials  Yue Han, MD, Yuxin Chen,

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials  Yue Han, MD, Yuxin Chen,
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,
Rising prevalence of asthma is sex-specific in a US farming population

Rising prevalence of asthma is sex-specific in a US farming population
A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,

Similar presentations

Ads by Google